LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥.
“Nexus Pharmaceuticals is very pleased to announce the approval of Succinylcholine Chloride. This critical need drug has seen an increased demand due to the COVID-19 pandemic and Nexus will be ready to meet the challenge. This approval further cements Nexus’ commitment to alleviating the drug shortage crisis with sterile injectable products produced exclusively in the US and Europe,” said Mariam S. Darsot, CEO & President of Nexus Pharmaceuticals.
Nexus Pharmaceuticals’ Succinylcholine Chloride Injection will be available in cartons of 25 vials.
About Succinylcholine Chloride Injection, USP
Succinylcholine Chloride Injection, USP is a sterile, nonpyrogenic solution to be used as an ultra-short-acting, depolarizing, skeletal muscle relaxant. Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
For prescribing information, please see the following link.
About Nexus Pharmaceuticals Inc.
Nexus Pharmaceuticals Inc., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.
¥QUELICIN is a registered trademark of Hospira, Inc., a wholly-owned subsidiary of Pfizer Inc.